Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation

              Author:Vaidya, Sagar   Dickson, Louise   Tolando, Roberto   Scholl, Celina   Charles, Michelle   Ossola, Dino   Matthews, Kim   Scott, Graham   Bexon, Martin   Castricum, Jesminne   Kremer, Philip   Dawson, Lee   Carlton, Mark   Brice, Nicola   

              Session Name:P8: Aging, Dementia, and Behavioral Neurology: Non-AD Treatments  

              Topic:Aging, Dementia, and Behavioral Neurology  

              Program Number:P8.016  

              Author Institution:Cerevance, La Jolla, CA  

              Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease

              Author:Chou, Kelvin   Brice, Nicola   Scholl, Celina   Charles, Michelle   Vaidya, Sagar   Dawson, Lee   Carlton, Mark   

              Session Name:P11: Movement Disorders: Therapeutics in Study for Parkinson's Disease  

              Topic:Movement Disorders  

              Program Number:P11.017  

              Author Institution:University of Michigan Health, Department of Neurology, Ann Arbor, MI  Cerevance, Cambridge , United Kingdom  Cerevance, La Jolla, CA